Cuervo Vaccine, a Seattle-based company, recently secured $60 million in a Series A financing round. The company, which works to develop safe and highly effective immunizations designed to fight off infectious diseases, plans to use the funding to continue its development of the next generation of subunit vaccines, specifically CRV-101, which is a vaccine to prevent shingles in older adults.
“I’m excited to close this financing and begin working with such a world-class group of investors,” said George Simeon, CEO of Curevo Vaccine.